natgillin/translations-raw huggingface dataset:
A method of removing metals from hydrocarbon feedstock using esters of carboxylic acids or combinations thereof, comprising the steps of: mixing a hydrocarbon stream containing metals and salts thereof, wherein the metal includes calcium and its salt is calcium naphthenate, with an effective metal removing amount of an aqueous extraction solution of non-precipitating and non-fouling additive comprising a chemical compound selected from a group consisting of: 
Metoda uklanjanja metala iz ugljikovodične sirovine upotrebom estera karboksilnih kiselina obuhvaća sljedeće korake: a) = miješanje protoka ugljikovodika koja sadrži metale i njihove soli pri čemu je metal kalcij a njegova sol je kalcij naftenat, s količinom vodene ekstrakcije koja učinkovito uklanja metal -otopinom aditiva koji se ne taloži i koji ne onečišćuje a koji sadrži kemijski spoj iz grupe koja se sastoji od: i)
The conveyor chain of claim 2, wherein said circle segment is a segment of a circle having a first diameter greater than the width of the conveyor chain and centered on the second axis. 
Transporti lanac prema zahtjevu 2 ili 3, naznačen time, da spomenuti kružni odsječak je odsječak kruga koji ima PrVI promjer veći nego što je širina transportnog lanca i centriran je na drugoj osi.
Additional therapeutic agents include those also targeting HCV, targeting a different disease causing agent, or those enhancing the immune system. 
Kombinacija prema patentnom zahtjevu 1 gdje dodatno terapeutsko sredstvo ciljano djeluje na HCV ili pojačava imunološki sustav. 4.
System according to the claim 1, characterised in that the cable rope (13) consists of an electric cable (9) in the middle, closely wrapped in a steel plaited rope (38) of suitable mechanical, mainly strength and tensile characteristics. 
Sustav prema zahtjevu 1, naznačen time, da se kabelsko uže (13) sastoji od električnog kabla (9) u sredini, čvrsto i tijesno omotanog u čelično obloženo uže (38) s prikladnim mehaničkim svojstvima, uglavnom što se tiče jačine 1 vlačne čvrstoće.
and pharmaceutically acceptable salts thereof, where R is hydrogen or an acyl group. 
s ili njegova farmaceutski prihvatljiva sol, naznačen time da R je vodik ili acil skupina.
or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof; treating the compound of formula (7) or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof, with a base under suitable conditions to form a compound of formula (8): 
OH ili njegovu farmaceutski prihvatljivu sol, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese; obradi spoja formule (7), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, bazom u uvjetima pogodnim za dobivanje spoja formule (8):
or a pharmaceutically acceptable salt thereof or tautomer of said compound or salt. The compound, 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide, having the following structure, 
Spoj, naznačen time što je 1-([(2S,3S,4S)-3-etil-4-fluor-5-oksopirolidin-2-il]metoksi)-7-metoksiizokinolin-6- karboksamid; ili farmaceutski prihvatljiva sol navedenog spoja ili tautomer navedenog spoja ili soli.
The process according to any one of claims 1 to 18, wherein the surface-reacted calcium carbonate obtained by the process has a BET specific surface area of at least 20 m2/g, preferably at least 30 m2/g, more preferably at least 40 m2/g, even more preferably at least 50 m2/g, still more preferably at least 60 m2/g, yet more preferably at least 70 m2/g and most preferably at least 80 m2/g. 
Postupak prema bilo kojem od zahtjeva 1 do 18, naznačen time da površinski reaktivni kalcijev karbonat koji je dobiven sa postupkom ima specifičnu površinu prema BET-u od barem 20 m/g, poželjno barem 30 m"/g, još poželjnije barem 40 m//g, još više poželjno barem 50 m//g, još više poželjno barem 60 m'/g, još više poželjno barem 70 m'/g, te najpoželjnije barem 80 m"/g.
contacting peripheral mononuclear blood cells (PBMCs) derived from a first organism with a mutein of human interleukin-2 (hIL-2 mutein), wherein said hIL-2 mutein has an amino acid substitution in at least one of the positions 20, 88, or 126, numbered in accordance with the hIL-2 wild type sequence as set forth in SEQ ID NO: 1, to obtain a cell population which comprises regulatory T cells, and 
Uporaba mutanta humanog interleukina-2 (hIL-2 mutant), koji je označen odgovarajuće prema hIL-2 divljem tipu i koji sadrži supstituciju amino kiseline na najmanje jednom od položaja 20, 88 ili 126, for za dobivanje lijeka za liječenje i/ili prevenciju autoimune bolesti, naznačena time da
A device as claimed in claim 2, characterized in that said emulsion-forming means consist of at least one stirring element (104)for increasing emulsion of liquid components when the washing and separating container (1) is subjected to mechanical or manual stirring, a force equal to that imparted by manual action being sufficient to create said emulsion. 
Uređaj kao što je naveden u patentnom zahtjevu 2, naznačen time da se navedena sredstva za formiranje emulzije sastoje od najmanje jednog elementa za miješanje (104) za povećanje emulzije tekućih komponenti kada je kontejner (1) za pranje i odvajanje podvrgnut mehaničkom ili manualnom miješanju, pri čemu je sila jednaka onoj koja je korištena pri manualnoj radnji dovoljna da se stvori navedena emulzija.
The compound of the invention may be administered as part of a combination therapy with an agent for treatment of diabetes, obesity, dyslipidaemia or hypertension. 
Spoj za uporabu prema zahtjevu 17, naznačen time, da spoj se primjenjuje kao dio kombinacijske terapije sa sredstvom za liječenje dijabetesa, pretilosti, dislipidemije ili hipertenzije.
Additional TPAP (0.62g) was added after 2 hours and again (0.8g) after 15 hours. 
Bio je dodan dodatni TPAP (0.62 g) nakon 2 sata i opet (0.8 g) nakon 15 sati.
a bispecific antibody (Q153-G4k/J142-G4h/L180-k), wherein the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 12, the second polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 170, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 171. 
(u) bispecifično protutijelo, gdje prvi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 12, drugi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 170, a treći polipeptid 1 četvrti polipeptid su zajednički korišten L-lanac od SEQ ID NO: 171.
The host cell of claim 6, wherein the host cell is a mammalian cell. 
Stanica domaćin u skladu s patentnim zahtjevom 17, naznačena time što je stanica domaćin stanica sisavca.
The muscarinic receptors are located at neuroeffector on, e.g. 
Muskarinski receptori su smješteni pri ncurocfcktoru, na pr.
An antigen binding protein of claim 4, wherein said antibody fragment is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a diabody, or a single chain antibody molecule. A nucleic acid molecule encoding an antigen binding protein of any one of claims 1-5. 
Protein koji veže antigen u skladu s bilo kojim od patentnih zahtjeva 1-3, pri čemu navedeni fragment protutijela je Fab fragment, Fab' fragment, F(ab'), fragment, Fv fragment, dijatijelo, ili jednolančana molekula protutijela; navedeni protein koji veže antigen je ljudsko protutijelo; ili navedeni protein koji veže antigen je monoklonsko protutijelo.
3 shows in sectional view details of a second embodiment of a beverage dispensing assembly according to the invention. 
Slika 3 prikazuje u presjeku pojedinosti druge izvedbe sklopa za točenje pića prema izumu.
Further provided is a method for modifying a genomic locus of interest in a pluripotent rat cell via targeted genetic modification, wherein the genomic locus of interest comprises (i) a first nucleic acid sequence that is complementary to the 5′ rat homology arm; and (ii) a second nucleic acid sequence that is complementary to the 3′ rat homology arm. In some such embodiments, the first and the second nucleic acid sequence is separated by at least 5 kb. 
(a) uvođenje u pluripotentnu štakorsku stanicu velikog vektora za ciljanje (LTVEC) koji sadrži ubačenu nukleinsku kiselinu flankiran s 5' homolognim dijelom komplementarno prvoj sekvenci nukleinske kiseline u genomskom lokusu od interesa i 3' homolognim dijelom komplementarno drugoj sekvenci nukleinske kiseline u genomskom lokusu od interesa, pri čemu je ukupan zbroj 5'1 3' homolognih dijelova najmanje 10 kb; i
After decanting the water, the gummy precipitate was washed with water (2×750 ml) then triturated with 300 ml methanol. 
Nakon dekantiranja vode, gumasti precipitat se opere s vodom (2 x 750 ml) pa triturira s 300 ml metanola.
subjecting the obtained compound of the formula 9 to a Suzuki reaction with a compound of the following formula 4 in the presence of palladium to prepare a compound of the following formula 1: wherein, A1, A2, A3, B1, B2, R1, R2, R3, R4, R5, R6, Ra, p and X are same as defined in claim 1; Y is Cl or Br; and Q is -B(OH)2 or 
[image] [image] pri čemu A1, A2, A3, B1, B2, R1, R2, R3, R4, R5, R6, Ra, p i X su isto definirano kao u zahtjevu 1; Y je Cl ili Br; i Q je -B(OH)2 ili [image] Chong Kun Dang Pharmaceutical Corp., KR
The method of claim 1, wherein the sample is a tumor, peripheral blood, a cell scraping, a hair follicle, a skin punch or a buccal sample. 
Postupak prema zahtjevu 1, naznačen time da je uzorak tumor, periferna krv, sastrugane stanice, folikula kose, uzorak kože ili bukalni uzorak.
The compound according to claim 1, 2 or 3 wherein R1 is Me, Et or is selected from a group of the following Formulae: and wherein Re is H or C1-4alkyl, and Rb is C1-4alkyl; or a pharmaceutically acceptable salt thereof. 
9. Spoj prema zahtjevu 1, 2 ili 3, naznačen time, da R' je Me, Et, ili je odabran iz skupine od sljedećih Formula:
The reaction mixture went dark-green after 5 minutes of the addition of butyl lithium. 
Dodatkom butil-litija, reakcijska smjesa postane tamno zelena nakon 5 minuta.
means (r715-C) for decoding service data of the FECFrame by an LDPC decoding scheme; means (r709-L1) for frequency-deinterleaving the preamble data symbols; 
sredstvo (r715-C) za dekodiranje demapiranog servisnog podatka pomoću dekodirajuće sheme LDPC, provjere pariteta niske gustoće, pri čemu su servisni podaci uključeni u pojedini ili višestruki PLP;
The conjugate according to any one of the previous claims, wherein the immunoglobulin Fc region is a derivative in which a region capable of forming a disulfide bond is deleted, certain amino acid residues are eliminated at the N terminal end of a native Fc form, a methionine residue is added at the N-terminal end of a native Fc form, a complement-binding site is deleted, or an antibody dependent cell mediated cytotoxicity (ADCC) site is deleted. 
Konjugat prema bilo kojem od zahtjeva 1 do 16, naznačen time da je Fc regija imunoglobulina derivat u kojem se regija koja može oblikovati disulfidnu vezu briše, određeni ostatci aminokiseline se uklanjaju na N-terminalnom kraju urođenog Fc oblika, ostatak metionina se dodaje na N-terminalni kraj urođenog Fc oblika, mjesto vezivanja komplementa se briše ili se briše mjesto stanične citotoksičnosti ovisne o protutijelima (ADCC).
The compound for use according to Claim 10, or a pharmaceutically acceptable salt thereof, for use in the treatment of bipolar disorder. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 10, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju bipolarnog poremećaja.
A pyrazolopyrimidine derivative of structural formula I: 
PATENTNI ZAHTJEVI 1. - Derivat pirazolpirimidina strukturne formule I:
wherein R1, R2 and R3 have the meanings defined in claim 1 and R6 is 2-hydroxyphenyl with carbonyldiimidazole or thiocarbonyldiimidazole in a suitable solvent and subsequent reaction of the product thus formed with amine NHR4R5 wherein R4 and R5 have the meaning defined in formula (1). 
(111) gdje Ri, R2 i Rs znače kao što je definirano u patentnom zahtjevu 1, a R4 je 2-hidroksifenil, s karbonildiimidazolom ili tiokarbonildiimidazolom u pogodnom otapalu, te naknadnom reakcijom tako dobivenog produkta s aminom NHR4Rs, gdje R4 i Rs znače kao što je definirano za formulu (1).
The sealing material can be constituted of both inelastic material and resilient material such as in layers, filler-matrix or blend or other forms. 
Materijal za brtvljenje može biti načinjen i od neelastičnog materijala i od elastičnog materijala, kao što je definirano u patentnim zahtjevima, kao na primjer u slojevima, matrici punila ili mješavine ili u nekim drugim oblicima.
The method of claim 1, wherein modifying comprises replacing at the endogenous MHC II a gene locus a nucleotide sequence encoding a non-human animal MHC II a polypeptide with the first nucleotide sequence encoding the chimeric human/non-human MHC II a polypeptide and/or replacing at the endogenous MHC II B gene locus a nucleotide sequence encoding a non-human animal MHC II B polypeptide with the second nucleotide sequence encoding the chimeric human/non-human MHC II B polypeptide. 
Postupak prema patentnom zahtjevu 1, naznačen time, da modificiranje obuhvaća sljedeće: na endogenom MHC II-a-gen-lokusu, zamjenu nukleotidne sekvence koja kodira glodarski MHC II-a-polipeptid s prvom nukleotidnom sekvencom koja kodira kimerni ljudski/glodarski MHC II-a-polipeptid i/ili na endogenom MHC II-B-gen-lokusu, zamjenu nukleotidne sekvence koja kodira glodarski MHC II-B-polipeptid s drugom nukleotidnom sekvencom koja kodira kimerni ljudski/glodarski MHC II-B-polipeptid.
crosslinking said mixture formed in step b), said crosslinking being carried out under conditions favourable to the covalent coupling of said hyaluronic acid and of said endogenous polyamine(s), 
umrežavanje navedene smjese nastale u koraku b), pri čemu se navedeno umrežavanje provodi u uvjetima povoljnim za kovalentno vezanje navedene hijaluronske kiseline i navedenog(ih) endogenog(ih) poliamina,
at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000; and 
(1) najmanje jedan polietilen oksid koji ima, prema Teološkim mjerenjima, približnu molekularnu težinu od najmanje 1,000,000; te
A compound for use in the treatment or prevention of tuberculosis and related diseases, as antimicrobial drug, which is represented by Formula (Ib) 
Spoj opće formule (Ia) za uporabu u liječenju i/ili prevenciji mikobakterijskih infekcija uzrokovanih, netuberkuloznim mikobakterijama (NTM), Mycobacterium leprae, i multirezistentnom Mycobacterium tuberculosis, naznačeno time da
The antibody or antigen-binding fragment thereof as claimed in any one of claims 1-7, wherein the heavy chain has an amino acid sequence of SEQ ID NO:160. 
Protutijelo ili njegov fragment koji se veže na antigen prema zahtjevu 7, naznačen(o) time, da jaki lanac ima jednu amino kiselinsku sekvencu od SEQ ID NO:51.
The topical gel composition of claim 1, wherein the total polyol comprises about 4.5% to 6.5% (w/w) a first polyol, and one or more additional polyols. 
Kompozicija topičkog gela prema zahtjevu 6, pri čemu ukupni poliol sadrži od oko 4,5% do 6,5% (w/w) prvog poliola.
A dose counter as claimed in claim 7, wherein the means to prevent reverse rotation comprises at least one pawl arranged to engage the ratchet teeth of the gear wheel. 
Brojač doze u skladu s patentnim zahtjevom 10, pri čemu sredstvo za sprečevanje reverzne rotacije obuhvaća najmanje jedan zapinjač postavljen za prihvaćanje zapornog zuba nazubljenog kotača (130).
Results are expressed as the percentage of inhibition respect to control (adhesion of the cells in the absence of compounds). 
Rezultati su izraženi kao postotak inhibicije u odnosu na kontrolu (adhezija stanica u odsutnosti spojeva).
The use of claim 28, wherein said crystalline trans-(±)-A9-tetrahydrocannabinol is delivered to the lungs of said mammal from a mechanical device suitable for pulmonary administration and capable of depositing said crystalline trans-(±)-A9-tetrahydrocannabinol of a mammal, preferably is selected from the group consisting of powder inhaler, a unit dose inhaler, a metered dose inhaler, a pump spray and a nebulizer. 
Upotreba prema zahtjevu 28, naznačena time da je navedeni kristalni trans-(±)-A9-tetrahidrokanabinol dostavljen u pluća navedenog sisavca iz mehaničkog uređaja pogodnog za plućnu primjenu i sposobnog za dostavljanje navedenog kristalnog trans-(±)-A9-tetrahidrokanabinola sisavcima, koji je poželjno odabran iz grupe koja sadrži inhalator praška, inhalator koji sadrži jediničnu dozu, ihnalator s brojačem doza, sprej pumpicu i nebulizator.
3984(3) Form H-1 according to claim 1 having a purity of at least 95 weight percent. 
Oblik H-1, u skladu sa zahtjevom 1, sa čistoćom od najmanje 95% masenog udjela.
The pharmaceutical preparation of claim 1, wherein the concentration of methylnaltrexone or salt thereof ranges from about 1.0 to about 50.0 mg/ml. 
Farmaceutski pripravak prema zahtjevu 1, naznačen time da se koncentracija metilnaltreksona ili njegove soli nalazi u rasponu od 0,01 do 100 mg/ml, ili od 1,0 do 50,0 mg/ml.
an isolated nucleic acid encoding a DA polypeptide according to claim 9, or; 
Biljka koja obuhvaća izolirani DA-polipeptid prema zahtjevu 9; ili izolirana nukleinska kiselina koja kodira l1.
The mixture was allowed to react for 10 min. at ambient temperature, then 100 µL of a 0.43 M stock solution of 4-amino- N -thiazol-2-yl-benzamide in DMF was added. 
Ostavi se da smjesa izreagira kroz 10 minuta na sobnoj temperaturi, potom se doda 100 ul 0.43 M kupljene otopine 4-amino-N-tiazol-2-il-benzamida u DMF-u.
at least one substitution selected from the group consisting of: (1) F243L; 
(A) najmanje jedne zamjene, koju se bira iz skupine koju čine: (1) F243L;
In another example, the kit may comprise a multidose dry powder inhalation device containing in the reservoir thereof a dry powder comprising (A) and a multidose dry powder inhalation device containing in the reservoir thereof a dry powder comprising (B). 
U drugom primjeru, komplet se može sastojati od višedozne inhalacijske naprave sa suhim prahom, koja naprava u svom rezervoaru ima suhi prah koji sadrži (A) i višedozne inhalacijske naprave sa suhim prahom, koja u svom rezervoaru ima suhi prah koji sadrži (B).
The fragrance was then added with stirring for about 2 minutes. 
Zatim se doda miris uz miješanje oko 2 minute.
A system according to any of Claims 1 to 3, wherein the transmitter includes a housing which contains a diagram of a boat and at least one control that is positioned to correspond to a component of the boat to be controlled. 
Sustav u skladu s patentnim zahtjevom 1 ili 2, naznačen time da odašiljač uključuje kućište na kojem se nalazi dijagram plovila i najmanje jedna upravljačka kontrola koja je postavljena tako da odgovara komponenti na plovilu kojom se treba upravljati.
The residue was purified by flash chromatography (SiO2) using 30% ethyl acetate-hexanes to give the desired product (1.64 g) a brown oil. 
Ostatak se pročisti svjetlosnom kromatografijom (Si02) uporabom 30% etil acetat-heksana da bi se dobio željeni produkt (1.64 g) kao smeđe ulje.
Most preferably, R1 is a hydrogen atom. 
R, je atom vodika; ili -
The method of any of items 1 to 16, wherein the CD19xCD3 bispecific single chain antibody construct is to be administered in a daily dose of 10µg to 100µg per square meter patient body surface area. 
Konstrukt namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt treba primijeniti u dnevnoj dozi od 10 ug do 100 ug/m' tjelesne površine pacijenta.
A linker represented by the following formula: 
Spoj predstavljen sljedećom formulom [image]
Crystalline butanol solvate of the compound of formula (IV) 
Kristalna butanolska otopina, naznačena time što je spoj formule (IV) nm
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) fluopyram. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fenpropimorf.
contacting a compound in the presence of which less of said complex is formed in step (c) in vitro with a mammalian enteroendocrine cell; and 
(d) stavljanja u kontakt spoja u prisutnosti u kojoj se formira manje kompleksa iz koraka (c) in vitro s enteroendokrinom stanicom sisavca; te
A compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, for use in the treatment of diseases and disorders ameliorated by the inhibition of LTA4H, wherein the diseases and disorders are selected from acute or chronic inflammation, anaphylactic reactions, allergic reactions, atopic dermatitis, psoriasis, acute respiratory distress syndrome, immune complex-mediated pulmonary injury and chronic obstructive pulmonary disease, inflammatory bowel diseases, gastrointestinal ulcers, neutrophilic dermatoses, immune-complex-mediated glomerulonephritis, autoimmune diseases, vasculitides, cardiovascular disorders, sepsis, inflammatory and neuropathic pain including arthritic pain, periodontal disease, ear infections, migraine, benign prostatic hyperplasia, Sjogren-Larsson Syndrome and cancers. 
Spoj prema bilo kojem od zahtjeva 1 do 14 i/ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da se upotrebljava u liječenju bolesti ili poremećaja koji se poboljšavanju putem inhibiranja LTA4H, pri čemu su bolesti 1 poremećaji odabrani od sljedećih: akutne ili kronične upale, anafilaktičke reakcije, alergijske reakcije, atopijski dermatitis, psorijaza, sindrom akutnog respiratornog poremećaja, plućna ozljeda posredovana imunokompleksom i kronična opstrukcijska plućna bolest, upalna bolest crijeva, gastrointestinalni ulceri, neutrofilne dermatoze, glomerulonefritis posredovan imunokompleksom, autoimune bolesti, vaskulitidi, kardiovaskularni poremećaji, sepse, upalni 1 neuropatski bolovi uključujući bolove od artritisa, periodontalna bolest, infekcije uha, migrene, benigna hiperplazija prostate, sindrom Sjogren-Larsson i rak.
The fluid pressure can act on the sealing material such that the sealing material is pressed both against the enclosure member and the outer surface of the capsule. 
Fluid pod tlakom može djelovati na materijal za brtvljenje na takav način da se materijal za brtvljenje potisne i na element koji obuhvaća čahuru i na vanjsku površinu čahure.
In yet another embodiment of the composition described herein, the rasagiline base present in the composition is crystalline rasagiline base. In yet another embodiment of the composition described herein, the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier. In yet another embodiment of the composition described herein, the composition is in the form of an oral dosage form. 
Sastav prema patentnom zahtjevu 7, naznačen time, da jest bez rasagilinske baze. Sastav prema jednom od patentnih zahtjeva 7-10, naznačen time, da sadržaj rasagilina u obliku rasagilin citrata iznosi više od 50% ukupnog sadržaja rasagilina u sastavu.
Use of a compound according to any one of claims 1 to 22 in the manufacture of a medicament for use in the treatment or prophylaxis of skin cancer or melanoma; a bacterial or protozoal disease condition; a viral disease condition which may optionally be: Hepatitis C, HIV, or West Nile Virus; malaria. 
Uporaba spoja prema bilo kojem od zahtjeva 1 do 22, naznačena time, da se koristi u postupku liječenja ili profilakse kod raka kože ili melanoma; kod stanja bakterijskih ili protozoalnih oboljenja; kod stanja virusnih oboljenja koja opcijski mogu biti: Hepatitis C, HIV, ili Virus Zapadnog Nila; kod malarije. učinkovitom količinom spoja prema bilo kojem zahtjevu od 1 do 22.